Bavarian Nordic soars on news of study into Tecentriq dual-therapy

10 March 2017

Denmark’s Bavarian Nordic (OMX: BAVA) has signed a deal with Roche (ROG: SIX) whereby the Swiss giant will supply Tecentriq (atezolizumab) for a clinical study testing the antibody in combination with cancer vaccine CV301.

Bavarian Nordic will undertake a Phase II study involving a sub-group of bladder cancer patients with disease progression, a patient population where Tecentriq has accelerated approval in the USA. Shares in the company are up 7% following the announcement.

Bavarian Nordic will be responsible for conducting the clinical trial, which is expected to kick off this year, and both companies will share the data that results from it.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK